Loading...
XPARDIM
Market cap19bUSD
Dec 20, Last price  
185.20EUR
1D
0.11%
1Q
7.99%
Jan 2017
208.82%
Name

Sartorius Stedim Biotech SA

Chart & Performance

D1W1MN
XPAR:DIM chart
P/E
58.19
P/S
6.49
EPS
3.18
Div Yield, %
0.74%
Shrs. gr., 5y
—
Rev. gr., 5y
18.02%
Revenues
2.78b
-20.53%
484,301,000521,053,000268,836,000367,996,000401,231,000432,949,000477,300,000543,964,000588,378,000683,524,000884,331,0001,051,611,0001,081,033,0001,212,152,0001,440,570,0001,910,081,0002,886,977,0003,492,700,0002,775,500,000
Net income
310m
-64.65%
22,026,00029,019,0004,742,00013,104,00029,092,00038,511,00043,190,00056,756,00066,276,00072,472,000117,999,000153,678,000161,088,000208,052,000234,574,000335,932,000414,400,000876,100,000309,700,000
CFO
630m
+2.84%
43,852,00051,715,00026,021,00047,226,00091,855,00072,759,00060,593,00048,927,00090,106,000111,312,000142,789,000156,659,000174,689,000227,289,000310,129,000416,879,000695,971,000612,300,000629,700,000
Dividend
Apr 02, 20240.69 EUR/sh

Profile

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
URL
https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa
IPO date
Oct 20, 1994
Employees
11,135
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,775,500
-20.53%
3,492,700
20.98%
2,886,977
51.14%
Cost of revenue
2,287,700
2,391,800
1,976,229
Unusual Expense (Income)
NOPBT
487,800
1,100,900
910,748
NOPBT Margin
17.58%
31.52%
31.55%
Operating Taxes
89,000
250,500
232,411
Tax Rate
18.25%
22.75%
25.52%
NOPAT
398,800
850,400
678,337
Net income
309,700
-64.65%
876,100
111.41%
414,400
23.36%
Dividends
(132,700)
(116,100)
(62,683)
Dividend yield
0.14%
Proceeds from repurchase of equity
1,300
BB yield
Debt
Debt current
79,100
23,900
40,444
Long-term debt
3,717,400
1,222,300
664,011
Deferred revenue
Other long-term liabilities
126,700
225,300
469,850
Net debt
3,639,100
1,114,200
466,059
Cash flow
Cash from operating activities
629,700
612,300
695,971
CAPEX
(473,600)
(430,600)
(323,987)
Cash from investing activities
(2,722,700)
(957,500)
(465,226)
Cash from financing activities
1,986,100
220,700
(71,711)
FCF
(45,700)
182,021
434,023
Balance
Cash
116,600
133,000
237,347
Long term investments
40,800
(1,000)
1,049
Excess cash
18,625
94,047
Stockholders' equity
2,673,200
2,514,200
1,753,510
Invested Capital
6,463,275
3,665,500
2,569,520
ROIC
7.87%
27.28%
27.55%
ROCE
7.09%
28.64%
32.65%
EV
Common stock shares outstanding
92,161
92,163
92,177
Price
482.40
65.66%
Market cap
44,466,102
65.66%
EV
45,009,522
EBITDA
725,400
1,282,600
1,052,304
EV/EBITDA
42.77
Interest
138,500
18,600
10,398
Interest/NOPBT
28.39%
1.69%
1.14%